Bayer is reeling from the aftermath of the acquisition of Monsanto, which has produced a series of unexpected lawsuits that are threatening to bring down the conglomerate. What to do with a former symbol of Germany’s industrial might that is now plagued by problems and whose stock price is hugely undervalued? Is it an opportunity for an activist investor?